A real-world study of peanut oral immunotherapy in children younger than 3 has shown the approach is safe and effective at ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Achieving and maintaining clinical remission for up to 2 years is feasible for nearly one third of patients with severe ...

The rise of the home barista has long been thought to add extra pressure on cafés' bottom lines, but is that necessarily the ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today ...

These patients began peanut OIT at a significantly higher mean dose (450 mg vs 25 mg peanut protein) and reached maintenance dosing with fewer clinic visits (mean difference, 4.5 visits ...

Treatment with cenobamate may reduce seizure frequency among patients with drug-resistant epilepsy after 3 months.

Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 ...

The Food and Drug Administration has granted Fast Track designation to bempikibart for the treatment of alopecia areata.

When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high drug prices as a reporter for years. What I discovered shocked ...

All participants treated with orforglipron were initially given a starting dose of 1mg once daily and then were increased in a step-wise approach to their respective maintenance dose. The primary ...

In the switching and maintenance groups, mean percent improvement from baseline ... Yuflyta is supplied as a 80mg/0.8mL and 40mg/0.4mL single-dose prefilled auto-injector; a 80mg/0.8mL and 40mg ...